Please note that this product (marked as Esperoct) was withdrawn from the Community Register of designated orphan medicinal products in May 2019 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

On 26 April 2012, orphan designation (EU/3/12/995) was granted by the European Commission to Novo Nordisk A/S, Denmark, for pegylated recombinant factor VIII for the treatment of haemophilia A. This medicine is now known as turoctocog alfa pegol.


Key facts

Active substance
PEGylated recombinant factor VIII (turoctocog alfa pegol)
Disease / condition
Treatment of haemophilia A
Date of first decision
EU designation number

Review of designation

Sponsor's contact details

Novo Nordisk A/S
Novo Alle 1
2880 Bagsvaerd
Telephone: +45 44 44 88 88
Telefax: +45 44 49 05 55

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating